Androgen receptor and soy isoflavones in prostate cancer

• Published in: Molecular and clinical oncology 2019-02, Vol.10 (2), p.191-204
• Main Authors: Sivoňov, Monika, Kapl n, Peter, Tatarkov, Zuzana, Lichardusov, Lucia, Dušenka, R bert, Jurečekov, Jana
• Format: Article
• Language: English
• Subjects: Amino acids; Androgen receptors; Androgens; Antigens; Breast cancer; Cancer prevention; Cancer therapies; Cancer treatment; Care and treatment; Cell cycle; Development and progression; Genetic aspects; Health; Health aspects; Heat shock proteins; Hormones; Isoflavones; Kinases; Ligands; Mortality; Oncology; Prostate cancer; Retirement benefits; Review; Sex hormones; Soy products; Steroid hormones; Studies; Testosterone
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2018.1792

Androgens and androgen receptor (AR) play a critical role not only in normal prostate development, but also in prostate cancer. For that reason, androgen deprivation therapy (ADT) is the primary treatment for prostate cancer. However, the majority of patients develop castration-resistant prostate cancer, which eventually leads to mortality. Novel therapeutic approaches, including dietary changes, have been explored. Soy isoflavones have become a focus of interest because of their positive health benefits on numerous diseases, particularly hormone-related cancers, including prostate and breast cancers. An important strategy for the prevention and/or treatment of prostate cancer might thus be the action of soy isoflavones on the AR signaling pathway. The current review article provides a detailed overview of the anticancer potential of soy isoflavones (genistein, daidzein and glycitein), as mediated by their effect on AR.